|
ACS Nano
|
20 |
|
|
|
Acta Biomaterialia
|
25 |
|
|
|
Advanced Functional Materials
|
9 |
|
|
|
Advanced Materials
|
1 |
|
|
|
American Journal of Clinical Nutrition
|
7 |
|
|
|
American Journal of Epidemiology
|
6 |
|
|
|
American Journal of Human Genetics
|
1 |
|
|
|
American Journal of Obstetrics and Gynecology
|
1 |
|
|
|
American Journal of Pathology
|
7 |
|
|
|
American Journal of Respiratory and Critical Care Medicine
|
64 |
|
Sub-phenotypes of pneumonia defined by pulmonary histopathological features
|
|
Idiopathic Pulmonary Fibrosis Risk Loci in East Asian Populations Mirror those of European Populations
|
|
Deupirfenidone Compared with Pirfenidone and Placebo in Idiopathic Pulmonary Fibrosis (ELEVATE-IPF): a Phase 2b Randomized Placebo-Controlled Trial
|
|
Phase 2b trial of inhaled imatinib for treatment of pulmonary arterial hypertension
|
|
Molecular endotypes predict differential response to immunosuppressant therapy in non–idiopathic pulmonary fibrosis interstitial lung disease
|
|
Mast Cells and Endothelial Cells Mediate Interleukin-33 and ST2 Responses in Distal COPD Lungs
|
|
Pamufetinib (TAS-115) for Chronic Fibrosing Interstitial Lung Diseases with a Progressive Phenotype: A double-blind, multicenter, phase 2b Clinical Trial
|
|
Mosaic Loss of Y chromosome associates with lung function, emphysema and epigenetic aging
|
|
Discriminative Performance and Clinical utility of COPD Exacerbation Categories for Predicting Future Exacerbations
|
|
Standalone Prognostication of Idiopathic Pulmonary Fibrosis Using Attention-Based Deep Learning
|
|
CES1 Deficiency is Associated With Metabolic Reprograming and Endothelial Dysfunction in Pulmonary Arterial Hypertension
|
|
Pulmonary Rehabilitation is Associated with Increased 1-Year Survival in Stable COPD
|
|
The Long-term Pneumonia Mortality Index. An International Multicenter Derivation and Validation Study for Patients with Community-Acquired Pneumonia
|
|
Clinical and transcriptomic risk factors for post-tuberculosis lung disease in a cohort of Kenyan adults
|
|
Motivational Interviewing and Air Cleaners for Smokers with COPD (MOVE): A Randomized, Double-Blind, Placebo-Controlled Trial
|
|
Extracellular Vesicle Cargo from Lipofibroblasts Mitigates COPD by Alveolar Type II Cell Restoration
|
|
Mucus plugs in chronic obstructive pulmonary disease are heterogeneous in size and shape and occur in relatively large airways
|
|
International validation of electronic nose technology as diagnostic tool for fibrotic interstitial lung diseases
|
|
Lower airway immunophenotyping in severe preschool wheeze reveals distinct clusters described by heterogeneity in neutrophil phenotypes
|
|
Effect of Dupilumab on Mucus Burden in Patients with Moderate-to-Severe Asthma: The VESTIGE Trial.
|
|
Mucus Plugs-associated Gene Expression Identifies Pathophysiology Shared with Chronic Bronchitis.
|
|
Phenotyping Asthma and/or COPD Using 129Xe MRI and Comprehensive Physiologic Testing.
|
|
Patient Factors and Clinical Efficacy of Early Identification and Treatment of COPD and Asthma.
|
|
p300-Dependent Modulation in Regulatory T Cells Plays a Crucial Role in Allergic Asthma.
|
|
Outcomes of a Typical Fibrotic Hypersensitivity Pneumonitis Pattern on Chest Computed Tomography
|
|
Airway Epithelial Heterogeneity and Mucus Plugging in Asthmatic Bronchioles.
|
|
Upper Airway Microbiome, Mucociliary Function, and Clinical Outcomes in Bronchiectasis: Data from the EMBARC-BRIDGE Study.
|
|
Cardiopulmonary Hemodynamic Determinants of Long-Term Survival in Sickle Cell Disease: Insights from the ETENDARD Study.
|
|
Randomized Sham Controlled Trial of Targeted Lung Denervation in Patients with COPD (AIRFLOW-3).
|
|
Mucus Plugs Correlate with Small Airway Remodelling in Asthma: A Case-Control Study.
|
|
Associations of High Attenuation Area-related Proteomic Biomarkers with Fibrotic or Subpleural Interstitial Lung Abnormalities.
|
|
One-Year Change in Quantitative Computed Tomography Is Associated with Meaningful Outcomes in Fibrotic Lung Disease.
|
|
Ionocyte CFTR Coordinates Chloride Absorption and Secretion to Balance Airway Fluid.
|
|
Active Antigen-Specific Adaptive Immune Responses Are Shared among Patients with Progressive Fibrotic Interstitial Lung Disease.
|
|
Distinct Morphological Types of Small Airway Obstructions in Smokers with Emphysema and End-Stage COPD.
|
|
Impact of Elexacaftor/Tezacaftor/Ivacaftor on Glucose Tolerance and Abnormal Glucose Metabolism: A Phase 3b, Open-Label Clinical Trial.
|
|
Impact of Sleep Apnea on Perivascular Diffusivity and Cognition: A 4-Year Prospective Cohort Study.
|
|
Inflammation and Obesity Correlate in Pulmonary Hypertension but Associate with Diverging Outcomes.
|
|
Hemodynamics and Phosphodiesterase-5 Inhibitor Treatment Associated with Survival in ILD-PH: A PVRI GoDeep Meta-Registry Analysis.
|
|
Non-Coding DNA Variants Increase the Genetic Diagnostic Yield in Primary Ciliary Dyskinesia.
|
|
A Large-Scale Single-Cell Atlas Reveals the Peripheral Immune Panorama of Bacterial Pneumonia.
|
|
Right Ventricular Strain and Outflow Tract Velocity Time Integral Are Associated with Mortality in Critically Ill Patients with Pulmonary Embolism
|
|
Proteomic Biomarkers of Survival in Non–Idiopathic Pulmonary Fibrosis Interstitial Lung Disease
|
|
Clustering Patients with Pulmonary Hypertension Using the Plasma Proteome
|
|
Visual and Quantitative Interstitial Lung Abnormality Progression in COPDGene.
|
|
A Long-Term Physical Activity Coaching Program for Patients with COPD: A Randomized Controlled Trial.
|
|
A Quantitative Imaging Measure of Progressive Pulmonary Fibrosis.
|
|
Molecular Phenotyping of Sepsis and Differential Response to Fluid Resuscitation.
|
|
Endotypes of Pseudomonas aeruginosa Infection in Bronchiectasis Are Associated with Inhaled Antibiotic Response: Results from Two Randomized, Double-Blind, Placebo-controlled Phase III Trials (ORBIT 3 and ORBIT 4).
|
|
The Plasma Proteome in Community-acquired Pneumonia: Pathophysiology, Outcome and 10-Year Risk.
|
|
Lipid Ratios for Diagnosis and Prognosis of Pulmonary Hypertension
|
|
Associations of Prepandemic Lung Function and Structure with COVID-19 Outcomes: The C4R Study
|
|
Dual αvβ6 and αvβ1 Inhibition over 12 Weeks Reduces Active Type I Collagen Deposition in Individuals with Idiopathic Pulmonary Fibrosis: A Phase 2, Double-Blind, Placebo-controlled Clinical Trial
|
|
Deep Learning Estimation of Small Airway Disease from Inspiratory Chest Computed Tomography: Clinical Validation, Repeatability, and Associations with Adverse Clinical Outcomes in Chronic Obstructive Pulmonary Disease
|
|
Clinical Remission by a Comprehensive Severe Asthma Management Strategy Guided by Airway Inflammometry and Bioimaging.
|
|
Performance Characteristics for Physiological Measures of Progressive Pulmonary Fibrosis.
|
|
Deficient FANCL Predisposes Endothelial Damage: A New Therapeutic Target for Pulmonary Hypertension.
|
|
Long-Term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Children ≥6 Years with Cystic Fibrosis and at Least One F508del Allele: A 192-Week, Phase 3, Open-Label Extension Study.
|
|
Metabolomic Evidence of Biological Overlap with HFpEF in a Subset of Pulmonary Arterial Hypertension.
|
|
<atl>Consistent Safety and Efficacy of Sotatercept for Pulmonary Arterial Hypertension in iBMPR2/i Mutation Carriers and Noncarriers: A Planned Analysis of a Phase II, Double-Blind, Placebo-controlled Clinical Trial (PULSAR)</atl>
|
|
Positioning Imatinib for Pulmonary Arterial Hypertension: A Dose-Finding Phase 2 Study
|
|
Camlipixant in Refractory Chronic Cough: A Phase 2b, Randomized, Placebo-controlled Trial (SOOTHE)
|
|
Select Airway Specialized Proresolving Mediators Are Associated with Recovery from Nonviral Chronic Obstructive Pulmonary Disease Exacerbations
|
|
Ivacaftor for Chronic Obstructive Pulmonary Disease: Results from a Phase 2, Randomized Controlled Trial
|
|
|
Analytical Chemistry
|
18 |
|
|
|
Anesthesiology
|
7 |
|
|
|
Angewandte Chemie International Edition
|
2 |
|
|
|
Annals of Emergency Medicine
|
5 |
|
|
|
Annals of Internal Medicine
|
8 |
|
|
|
Annals of Neurology
|
4 |
|
|
|
Annals of Surgery
|
7 |
|
|
|
Annals of the Rheumatic Diseases
|
7 |
|
|
|
Applied Physics Letters
|
5 |
|
|
|
Archives of Physical Medicine and Rehabilitation
|
6 |
|
|
|
Arthritis & Rheumatology
|
21 |
|
|
|
Blood
|
32 |
|
|
|
Brain
|
2 |
|
|
|
British Journal of Surgery
|
10 |
|
|
|
Cancer Cell
|
3 |
|
|
|
Cell
|
2 |
|
|
|
Cell Host & Microbe
|
3 |
|
|
|
Cell Metabolism
|
2 |
|
|
|
Cell Stem Cell
|
2 |
|
|
|
Chemical Science
|
4 |
|
|
|
Chest
|
75 |
|
|
|
Circulation
|
100 |
|
JNK2 Is a Stress Integrator Driving Atrial Fibrillation Pathogenesis in Aging via Gut-Heart Crosstalk.
|
|
The Natural History of Massive Left Ventricular Hypertrophy in Pediatric Hypertrophic Cardiomyopathy: A Multiregistry Analysis.
|
|
Phone-Based Intervention Under Nurse Guidance for Control of Hypertension After Stroke: A Randomized Multicenter Phase 3 Trial in Ghana.
|
|
Mir147 Limits the Contribution of Non-Foamy Macrophages to Atherosclerosis.
|
|
Cardiovascular-Kidney-Metabolic Syndrome Stages, Echocardiographic Characteristics, and Heart Failure Risk: The Atherosclerosis Risk in Communities Study.
|
|
The Fontan Outcomes Network: Findings After 2 Years and 1121 Participants.
|
|
Memantine for Premature Atrial Contractions: A Phase 2 Randomized Clinical Trial.
|
|
CRLF1 Secreted by Cardiac Fibroblasts Promotes Human Hypertrophic Cardiomyopathy
|
|
Differences in Disease Trajectory, Comorbidities, and Mortality in Sarcomeric and Nonsarcomeric Hypertrophic Cardiomyopathy.
|
|
A Critical Contribution of Cardiac Myofibroblasts in Right Ventricular Failure and the Role of UCP2 SNPs in the Predisposition to RV Decompensation in Pulmonary Arterial Hypertension.
|
|
TRIM28 Is an E3 Ligase of IRP2 Suppressing Ischemia/Reperfusion-Induced Myocardial Ferroptosis.
|
|
Small Extracellular Vesicle External Surface Adiponectin-Mediated Adipocytes/Cardiomyocytes Communication in Diabetic Ischemic Heart Failure.
|
|
PAM-VT 2 Study: Long-Term Scar Evolution and Ablation Lesion Assessment by Late Gadolinium Enhancement Cardiac Magnetic Resonance After Ventricular Tachycardia Ablation.
|
|
Aortic and Iliac Calcifications as Predictors of Aortic Dissection, Aneurysm Rupture, and Peripheral Vascular Disease: A Prospective Cohort Study from the DANCAVAS Trials.
|
|
Risk of Heart Failure Hospitalization for GLP-1 Receptor Agonists Versus DPP-4 Inhibitors or SGLT-2 Inhibitors in Patients With Type 2 Diabetes: A Target Trial Emulation.
|
|
CCR8 Expression on Regulatory T Cells Reveals Trajectories of Tissue Adaptation and Protects Against Myocardial Infarction-Induced Tissue Damage.
|
|
Elevated Pulmonary Artery Wedge Pressure in Group 1 Pulmonary Hypertension.
|
|
Prospective Associations of Obesity and Obesity Severity With 9 Cardiovascular Outcomes: The Cross-Cohort Collaboration.
|
|
Natural History of Patients With Histologically Proven Acute Eosinophilic Myocarditis.
|
|
Defining an Optimal Result of Transcatheter Tricuspid Valve Intervention: Results From the Tri-QOL Study
|
|
Systemic Embolic Events in Atrial Fibrillation: An Individual Patient Data Meta-analysis of 71 683 Participants Randomized to NOAC Versus Warfarin.
|
|
Association of Pre-Fontan Hemodynamics With Long-Term Outcomes After Fontan Palliation: A Study From the Pediatric Cardiac Care Consortium
|
|
CXCR6+ T Cells Drive Immune Checkpoint Inhibitor Myocarditis.
|
|
Prognostic Implications of Evolving Universal Definitions of Periprocedural Myocardial Infarction in Patients With Acute Coronary Syndrome.
|
|
Inhibition of Annexin A2 Facilitates PHB2-Mediated Mitophagy in Cardiomyocytes to Alleviate Cardiac Injury and Remodeling After Infarction.
|
|
Myocardial Recovery With Mechanical Circulatory Support Is Linked to Alternative Splicing and Subcellular Localization of CAMK2D.
|
|
Engineered Regulatory T Lymphocytes Promote Infarcted Heart Repair.
|
|
Endothelial Transcription Factor EB Protects Against Doxorubicin-Induced Endothelial Toxicity and Cardiac Dysfunction.
|
|
Bradycardia in Athletes: Prevalence, Mechanisms, and Risks.
|
|
Macrophage-Specific E3 Ubiquitin Ligase TRIM31 Reduces Atherosclerotic Plaque Formation by Targeting LOX-1.
|
|
IMPROVE-DiCE, a 2-Part, Open-Label, Phase 2a Trial Evaluating the Safety and Effectiveness of Ninerafaxstat in Patients With Cardiometabolic Syndromes.
|
|
S-Nitrosylation of Pyruvate Kinase Isoform 2 Drives Cardiac Fibrosis by Promoting Mitochondrial Fission.
|
|
Safety, Utility, and Outcomes of Procainamide Challenge for the Diagnosis and Exclusion of Brugada Syndrome.
|
|
Oxidized Phospholipids, Lipoprotein(a), and Cardiovascular Outcomes After Acute Coronary Syndrome
|
|
Leveraging a Genetic Proxy to Investigate the Effects of Lifelong Cardiac Sodium Channel Blockade.
|
|
OxLDL-Targeted Chimeric Antigen Receptor T Regulatory Cells Reduce Atherosclerotic Plaque Development.
|
|
Sacubitril-Valsartan for the Prevention of Anthracycline Cardiotoxicity in Patients With Elevated Cardiac Troponin I Concentration During Chemotherapy: A Double-Blind Randomized Placebo-Controlled Clinical Trial: The SARAH Trial.
|
|
Quantitative Identification of High-Risk Tricuspid Regurgitation by Cardiac Magnetic Resonance.
|
|
Cardiac Allograft Vasculopathy Inhibition with Alirocumab: The CAVIAR Trial.
|
|
Dapagliflozin to Reduce Early Recurrence After Catheter Ablation for Atrial Fibrillation: The DARE-AF Randomized Clinical Trial.
|
|
Incidence, Risk Factors, and Outcomes in Stressor-Associated Atrial Fibrillation: Insights from the VITAL-AF Trial
|
|
Deep Learning–Based Continuous QT Monitoring to Identify High-Risk Prolongation Events After Class III Antiarrhythmic Initiation
|
|
Triple Versus Dual Lipid-Lowering Therapy in Acute Coronary Syndrome: The ES-BempeDACS Randomized Clinical Trial.
|
|
Efficacy and Safety of Very Low Achieved LDL-Cholesterol in Patients with Prior Ischemic Stroke.
|
|
Prognostic Value of Exercise Right Ventricular-Pulmonary Arterial Coupling in Primary Mitral Regurgitation.
|
|
Combined Adaptive Immune Mechanisms Mediate Cardiac Injury After COVID-19 Vaccination.
|
|
IRF5 siRNA Nanoimmunotherapy: Restoring Macrophage Efferocytosis in Atherosclerosis.
|
|
Geometric Features of Ventricular Tachycardia Corridors in Patients With Ischemic Cardiomyopathy.
|
|
Nuclear eNOS Interacts With and S-Nitrosates ADAR1 to Modulate Type I Interferon Signaling and Endothelial Function.
|
|
The Role of the Collateral Circulation in Stable Angina: An Invasive Placebo-Controlled Study.
|
|
Short-Term Anticoagulation versus Dual Antiplatelet Therapy for Preventing Device Thrombosis Following Left Atrial Appendage Closure: The ANDES Randomized Clinical Trial.
|
|
Bailout Intracranial Angioplasty or Stenting After Thrombectomy for Acute Large Vessel Occlusion: 1-Year Outcomes of ANGEL-REBOOT.
|
|
Heart Stress and Blood Pressure Management in Older Adults: Post Hoc Analysis of the ASPREE Trial.
|
|
ALDH2/eIF3E Interaction Modulates Protein Translation Critical for Cardiomyocyte Ferroptosis in Acute Myocardial Ischemia Injury.
|
|
Hypercontractility and Oxidative Stress Drive Creatine Kinase Dysfunction in Hypertrophic Cardiomyopathy.
|
|
Transcatheter Closure of Patent Foramen Ovale With a Novel Biodegradable Device: A Prospective, Multicenter, Randomized Controlled Clinical Trial.
|
|
High-Voltage Focal Pulsed Field Ablation to Treat Scar-Related Ventricular Tachycardia: The First-in-Human VCAS Trial.
|
|
Single-Cell Splicing Isoform Atlas of the Adult Human Heart and Heart Failure.
|
|
Clinical and Prognostic Significance of Anomalous Origin of a Coronary Artery in Adults.
|
|
Screening-Detected Atrial Fibrillation and Cardiovascular Outcomes in Working-Age Adults.
|
|
PYGM Protects Against Myocardial Infarction by Enhancing Glycogenolysis and Facilitating Autophagic Flux.
|
|
Role of A2AR-D2R Dimerization and D2R-Biased Signaling in PDE10A-Mediated Cardiac Hypertrophy.
|
|
Fibroblast-Specific Loss of TGF-β Signaling Mediates Lipomatous Metaplasia in the Infarcted Heart.
|
|
TAX1BP3 Is a SUMOylated Nucleocytoplasmic Shuttling Protein and Protects Against Vascular Neointimal Hyperplasia.
|
|
Drug-Eluting Resorbable Scaffold Versus Balloon Angioplasty for Below-the-Knee Peripheral Artery Disease: 2-Year Results From the LIFE-BTK Trial.
|
|
Characterization and Application of Novel Exercise Recovery Patterns That Reflect Cardiac Performance: A Substudy of the SEQUOIA-HCM Trial.
|
|
Health Status Outcomes With Percutaneous Coronary Intervention and Coronary Artery Bypass Grafting in ISCHEMIA
|
|
Clinical Presentation and Outcomes After Surgery for Mitral Regurgitation: Real-World Insights From the MITRACURE International Registry.
|
|
Three-Year-Follow-Up of the NOTION-2 Trial: TAVR Versus SAVR to Treat Younger Low-Risk Patients with Tricuspid or Bicuspid Aortic Stenosis.
|
|
Ivabradine in Patients Undergoing Noncardiac Surgery: a Randomized Controlled Trial.
|
|
Sacubitril-Valsartan and Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy: The PRADA II Randomized Clinical Trial.
|
|
Biomarker-based ABC-AF Risk Scores for Personalized Treatment to Reduce Stroke or Death in Atrial Fibrillation - a Registry-based Multicenter Randomized Controlled Study.
|
|
Dapagliflozin in Patients Hospitalized for Heart Failure: Primary Results of the DAPA ACT HF-TIMI 68 Randomized Clinical Trial and Meta-Analysis of Sodium-Glucose Cotransporter-2 Inhibitors in Patients Hospitalized for Heart Failure.
|
|
Redefining the Genetic Architecture of Hypertrophic Cardiomyopathy: Role of Intermediate Effect Variants.
|
|
Peri-interventional Anesthesia Strategies for Transcatheter Aortic Valve Implantation: A Multicenter, Randomized, Controlled, Non-inferiority Trial.
|
|
Prognostic Role of Myocarditis-Like Episodes and Their Treatment in Patients With Pathogenic Desmoplakin Variants.
|
|
Transcatheter Aortic Valve Replacement With Balloon- Versus Self-Expandable Bioprostheses for the Treatment of Bicuspid Aortic Valve Stenosis
|
|
Human Single-Nucleus RNA Sequencing Identifies CD47 as a Therapeutic Target for Doxorubicin-Induced Cardiomyopathy.
|
|
Long-Term Outcomes of Early Surgery Versus Conventional Treatment for Asymptomatic Severe Mitral Regurgitation: A Propensity Analysis.
|
|
TBX5 and CHD4 Coordinately Activate Atrial Cardiomyocyte Genes to Maintain Cardiac Rhythm Homeostasis.
|
|
G Protein-Coupled Receptor Kinase 3 Exacerbates Diabetic Heart Injuries Through Direct Phosphorylation of Cannabinoid Receptor 2 in Humans and Mice.
|
|
Ponatinib, But Not the New Abl-Kinase Inhibitor Asciminib, Activates Platelets, Leukocytes, and Endothelial Cell TNF Signaling to Induce Atherosclerotic Plaque Inflammation, Myocardial Infarction, and Stroke.
|
|
Single-Cell Multi-Omics Identifies Specialized Cytotoxic and Migratory CD8+ Effector T Cells in Acute Myocarditis.
|
|
Hypertriglyceridemia as a Key Contributor to Abdominal Aortic Aneurysm Development and Rupture: Insights From Genetic and Experimental Models.
|
|
Evaluation of Lipoprotein(a) as a Prognostic Marker of Extracoronary Atherosclerotic Vascular Disease Progression.
|
|
Junctophilin-2 Regulates Store-Operated Calcium Entry to Drive Cardiac Fibroblast Activation, Fibrotic Repair, and Angiogenesis After Myocardial Infarction.
|
|
Association of Statin Treatment and Dose With the Clinical Course of Small Abdominal Aortic Aneurysms in Men: A 5-Year Prospective Cohort Study From 2 Population-Based Screening Trials.
|
|
The Impact of Fontan Circulatory Failure on Heart Transplant Survival: A 20-Center Retrospective Cohort Study.
|
|
New Algorithm for Estimating Left Ventricular Filling Pressure by Echocardiography.
|
|
Abelacimab Versus Rivaroxaban in Patients With Atrial Fibrillation on Antiplatelet Therapy: A Prespecified Analysis of the AZALEA-TIMI 71 Trial.
|
|
Family Screening in Relatives at Risk for Plakophilin-2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy.
|
|
Effect of Remote Ischemic Preconditioning on Myocardial Injury in Noncardiac Surgery: the PRINCE Randomized Clinical Trial.
|
|
Aortic Aneurysm Risk and Somatic JAK2V617FVariation: Insights From a Multicenter, Population-Based Cardiovascular Screening Study.
|
|
Burden of Cardiovascular Outcomes After SARS-CoV-2 Infection in South Korea and Japan: A Binational Population-Based Cohort Study.
|
|
Disruption of cTnT-Mediated Sarcomere-Mitochondrial Communication Results in Dilated Cardiomyopathy.
|
|
Genotype-Specific Outcomes of Desmosomal Cardiomyopathies.
|
|
Proteomic Signatures for Risk Prediction of Atrial Fibrillation.
|
|
Genomic Editing of a Pathogenic Mutation in ACTA2 Rescues Multisystemic Smooth Muscle Dysfunction Syndrome in Mice.
|
|
METTL3 Is Essential for Exercise Benefits in Diabetic Cardiomyopathy.
|
|
CD206+IL-4Rα+ Macrophages Are Drivers of Adverse Cardiac Remodeling in Ischemic Cardiomyopathy.
|
|
|
Clinical Infectious Diseases
|
5 |
|
|
|
Critical Care Medicine
|
12 |
|
|
|
Developmental Cell
|
2 |
|
|
|
Diabetes Care
|
13 |
|
|
|
Environmental Health Perspectives
|
1 |
|
|
|
Environmental Pollution
|
11 |
|
|
|
Environmental Research
|
17 |
|
|
|
Environmental Science and Technology
|
12 |
|
|
|
European Heart Journal
|
128 |
|
Cardiac resynchronization therapy with or without atrioventricular node ablation in atrial fibrillation: the CAAN-AF trial
|
|
PCSK9 inhibitor treatment and outcomes in patients with atherosclerotic cardiovascular disease but without prior ischaemic events: an observational study
|
|
New-onset postoperative atrial fibrillation management and outcomes: the VISION Cardiac Surgery cohort
|
|
Stroke and systemic embolism following atrial fibrillation ablation: the EMBOL-AF Global Registry
|
|
Atrial fibrillation density as a biomarker for ischaemic stroke risk prediction
|
|
Sex differences in cardiovascular–kidney–metabolic syndrome: the FINE-HEART pooled analysis
|
|
Risk prediction in patients with heart failure with preserved ejection fraction: the LIFE-Preserved model
|
|
Prediction of incident heart failure in established atherosclerotic cardiovascular disease: the SMART2-HF model
|
|
Artificial intelligence–based quantification of breast arterial calcifications to predict cardiovascular morbidity and mortality
|
|
Laminopathies: natural history and risk prediction of heart failure
|
|
Aficamten in symptomatic obstructive hypertrophic cardiomyopathy: the FOREST-HCM long-term study
|
|
SLC4A3-related short QT syndrome assessed in human induced pluripotent stem cell-derived cardiomyocytes: mechanisms of ventricular arrhythmia and sudden cardiac death
|
|
Nuclear AGO2 exacerbates heart failure with preserved ejection fraction through myocardial ketogenesis
|
|
Carotid plaque macrophage burden and inflammatory lipid-associated macrophage markers predict secondary major adverse cardiovascular events after endarterectomy
|
|
Switching from warfarin to direct oral anticoagulants in frail elderly Asian patients with atrial fibrillation: a Korean nationwide study
|
|
Aspirin use, lipoprotein(a), and calcific aortic valve disease: the Multi-ethnic Study of Atherosclerosis
|
|
Pelacarsen and lipoprotein(a) apheresis in secondary prevention: the Lp(a)FRONTIERS APHERESIS trial
|
|
Arrhythmias in congenitally corrected transposition of the great arteries: an international study
|
|
Soluble ST2 drives fulminant myocarditis progression via the IGF2R–YY1 mitochondrial axis
|
|
Macrophage SBK2 suppresses inflammation and atherosclerosis by NLRP3 phosphorylation
|
|
Spatial transcriptomics reveals a key role of fibroblast-like vascular smooth muscle cells in human atherosclerotic cell crosstalk and stability
|
|
Macrophage-specific circular RNA circHIPK2, inflammation, and fibrosis after myocardial infarction
|
|
Computed tomography-guided vs conventional catheter ablation for ventricular tachycardia: the InEurHeart trial
|
|
Heart failure in the Portuguese population aged ≥50 years: prevalence and phenotypes in the PORTHOS study
|
|
Subvalvular aortic stenosis in adults: clinical course and long-term outcomes
|
|
Frozen elephant trunk for acute type A aortic dissection: long-term outcomes over two decades
|
|
Peri-operative myocardial infarction/injury after non-cardiac surgery: association between cardiologist evaluation and outcomes
|
|
Heart failure with preserved ejection fraction in adults with congenital heart disease
|
|
Peripheral autonomic dysregulation in response to standing: a new form associated with cardiovascular disease, mobility reduction, and cognitive alterations
|
|
Risk-weighted apoB: a novel summary metric outperforming traditional lipid biomarkers in predicting coronary heart disease
|
|
Foundation models for electrocardiogram interpretation: clinical implications
|
|
Pulsed field vs radiofrequency ablation for paroxysmal atrial fibrillation: the BEAT PAROX-AF trial
|
|
Left bundle branch vs biventricular pacing: mechanistic insights from a canine model
|
|
Anthracycline cardiotoxicity: role of metabolic vulnerability induced by cardiac pressure overload
|
|
Congenital heart defects: familial recurrence patterns in Sweden
|
|
Complete revascularization timing in ST-segment elevation myocardial infarction and multivessel disease with heart failure: the OPTION–STEMI trial
|
|
Major arrhythmias in non-dilated left ventricular cardiomyopathy: a novel prediction score
|
|
The junctional protein associated with coronary artery disease predicts adverse cardiovascular events in patients with acute coronary syndromes at high residual risk
|
|
Adults with Fontan circulation: prognostic value of exercise pulmonary vascular resistance index
|
|
Catecholaminergic polymorphic ventricular tachycardia mediated by ryanodine receptor 2: a validated risk stratification
|
|
Physiology vs angiography-guided percutaneous coronary intervention in transcatheter aortic valve implantation: the FAITAVI trial
|
|
Mitral transcatheter edge-to-edge repair and outcomes according to baseline health status: the RESHAPE-HF2 trial
|
|
Atherosclerotic progression at sites of low shear stress is attenuated by myeloid-PlexinD1 deficiency through suppression of classical macrophage polarization
|
|
Combined clinical, metabolomic, and polygenic scores for cardiovascular risk prediction
|
|
Sex-specific cardiac ageing and sympathetic compensation: a translational study
|
|
Digital profile of children’s hearts: automated echocardiogram strain analysis facilitates earlier detection of cardiac dysfunction
|
|
Long forms of cardiac troponin T for myocardial infarction diagnosis: the SuperTROPO study
|
|
Diabetes and sudden cardiac death: a Danish nationwide study
|
|
Oestrogen-related receptor γ in sepsis-induced cardiomyopathy: role of cardiomyocyte subtype conversion
|
|
Osimertinib induces reversible cardiac dysfunction through the GATA4-MYLK3-MYL2 axis
|
|
The macrophage-derived motor protein KIF13B enhances MERTK-mediated efferocytosis and prevents atherosclerosis in mice
|
|
Women with chronic coronary artery disease: long-term outcomes after percutaneous coronary intervention vs coronary artery bypass grafting
|
|
Artificial intelligence-enhanced electrocardiography to predict regurgitant valvular heart diseases: an international study
|
|
Temporal trends in the use of oral anticoagulants and clinical outcomes in older, elderly, and very elderly patients with atrial fibrillation: a Danish nationwide study
|
|
Endotypes of angina with non-obstructive coronary arteries: a prospective multicentre study
|
|
Enhanced antigen presentation by macrophages promotes human atherosclerosis progression: therapeutic implications
|
|
High-sensitivity cardiac troponin I and risk of dementia: the 25-year longitudinal Whitehall II study
|
|
Dementia risk across blood pressure categories: a South Korean nationwide study
|
|
Genetic evaluation of early-onset atrial fibrillation: impact on patient management
|
|
Early outcomes of children with univentricular circulation undergoing Fontan surgery: the EuroFontan registry
|
|
Outcomes of moderate mixed aortic valve stenosis and regurgitation
|
|
Atrial cardiomyopathy: markers and outcomes
|
|
Blood pressure, plasma proteins, and cardiovascular diseases: a network Mendelian randomization and observational study
|
|
Left ventricular geometry, brain architecture, and cognition: an observational study
|
|
Sex differences in atrial fibrillation-related atrial remodelling assessed by electroanatomic mapping and biopsy
|
|
Antihypertensive treatment in young adults and cardiovascular risk: a population-based cohort study
|
|
EP4/ANXA2 axis in pulmonary arterial hypertension: therapeutic implications
|
|
Drug-coated vs non-drug-coated devices for femoropopliteal artery interventions: long-term outcomes of the SAFE-PAD study
|
|
Transcriptomic biomarkers related to cardiac disease in childhood cancer survivors: a case-control study
|
|
Left bundle branch area pacing vs right ventricular pacing for atrioventricular block: the MELOS RELOADED study
|
|
Early antiplatelet treatment for minor stroke following thrombolysis: the EAST trial
|
|
Endothelial plasticity in atrial fibrosis by integrating single-cell sequencing and genetic lineage tracing
|
|
Fulminant myocarditis: outcome predictors in an international cohort study
|
|
Cytosolic calcium handling signature: integration with clinical predictors enhances prediction of post-operative atrial fibrillation
|
|
Sex-specific outcomes after transcatheter or surgical treatment of aortic valve stenosis: the DEDICATE-DZHK6 trial
|
|
Surgical left atrial appendage occlusion in valvular heart disease without atrial fibrillation: the OPINION trial
|
|
Temporal modulation of antiplatelet therapy in high-risk patients undergoing complex percutaneous coronary intervention: the TAILORED-CHIP randomized clinical trial
|
|
C-reactive protein and cardiovascular risk among women with no standard modifiable risk factors: evaluating the ‘SMuRF-less but inflamed’
|
|
Arrhythmic genotypes in dilated cardiomyopathy and risk of advanced heart failure
|
|
Atrial fibrillation and atherosclerosis cause different vascular brain lesions on magnetic resonance imaging
|
|
Surgical myectomy for hypertrophic cardiomyopathy: procedural volume and outcomes
|
|
iLIPA/i, a risk locus for coronary artery disease: decoding the variant-to-function relationship
|
|
Withdrawal of heart failure therapy after atrial fibrillation rhythm control with ejection fraction normalization: the WITHDRAW-AF trial
|
|
Coronary function testing vs angiography alone to guide treatment of angina with non-obstructive coronary arteries: the ILIAS ANOCA trial
|
|
Aspirin, cardiovascular events, and major bleeding in older adults: extended follow-up of the ASPREE trial
|
|
Titin-related familial dilated cardiomyopathy: factors associated with disease onset
|
|
Low-density lipoprotein cholesterol and cardiovascular risk in the absence of calcifications on computed tomography: the Western Denmark Heart Registry
|
|
Cardiovascular benefit of continuous positive airway pressure according to high-risk obstructive sleep apnoea: a multi-trial analysis
|
|
Heparin administration at first medical contact vs immediately before primary percutaneous coronary intervention: the HELP-PCI trial
|
|
Kidney function trajectories before and after hospitalization for heart failure with reduced ejection fraction
|
|
Excessive glycosylation drives thoracic aortic aneurysm formation through integrated stress response
|
|
Cryoballoon vs radiofrequency ablation in persistent atrial fibrillation: the CRRF-PeAF trial
|
|
Mind the gaps: blood pressure variability and its impact on health
|
|
ApoB and Lp(a): core measures to assess cardiovascular risk
|
|
Colchicine for secondary prevention of vascular events: a meta-analysis of trials
|
|
Long-term trials of colchicine for secondary prevention of vascular events: a meta-analysis
|
|
Cumulative exposure to atherogenic lipoprotein particles in young adults and subsequent incident atherosclerotic cardiovascular disease
|
|
Radial vs femoral access for percutaneous coronary intervention: temporal trends and outcomes in the USA
|
|
First myocardial infarction: risk factors, symptoms, and medical therapy
|
|
Long QT syndrome in children and adolescents: risk factors and outcomes in a large German cohort
|
|
Natriuretic targets in acute heart failure with volume overload: are we misguided?
|
|
Urgent surgery vs fibrinolytic therapy for left-sided prosthetic valve thrombosis: a randomized trial
|
|
Atrial fibrillation in former world-class rowers: role of environmental and genetic factors
|
|
Emphasizing life-course prevention for atherosclerosis with focus on blood pressure
|
|
Patient–prosthesis mismatch after aortic valve replacement: one size does not fit all
|
|
Immune checkpoint inhibitor-associated myocarditis: a novel risk score
|
|
Plaque erosion: unmasking the complexity of atherosclerotic disease
|
|
Circadian patterns of atrial fibrillation and disease progression assessed by implanted loop recorders
|
|
Gut microbiota as predictors of recurrent cardiovascular events: challenges and future directions
|
|
Mode of revascularization for ischaemic cardiomyopathy: comparing apples with oranges?
|
|
Clinical implications of sex-related differences in severe aortic stenosis
|
|
Titanium-nitride-oxide-coated vs. drug-eluting stents in acute coronary syndromes: an individual patient data meta-analysis
|
|
A durable competitor or non-starter: is there a role for the biocompatible TiNO stent in acute coronary syndromes?
|
|
The Australian–New Zealand SCAD observational cohort study: major adverse cardiovascular events are associated with ticagrelor combined with aspirin, FMD, and history of stroke
|
|
Pre-treatment lysis time of plasma-derived fibrin clots and bleeding in patients on oral anticoagulants for atrial fibrillation in the ARISTOTLE trial
|
|
Preventive percutaneous coronary intervention for non-flow-limiting vulnerable atherosclerotic coronary plaques in diabetes: the PREVENT trial
|
|
Optimal medical care and coronary flow capacity-guided myocardial revascularization vs usual care for chronic coronary artery disease: the CENTURY trial
|
|
Beta-blocker interruption effects on blood pressure and heart rate after myocardial infarction: the AβYSS trial
|
|
Prediction of ventricular arrhythmic outcomes in suspected cardiac sarcoidosis: a comparison of cardiovascular magnetic resonance phenotyping vs. societal recommendations for implantable cardioverter-defibrillator placement
|
|
Empagliflozin enhances metabolic efficiency and improves left ventricular hypertrophy in a hypertrophic cardiomyopathy mouse model
|
|
Catheter ablation in congenital heart diseases: a French nationwide study
|
|
Checkpoint kinase Wee1 activation drives inflammation and hypertrophy through the protein kinase B/phosphoinositide 3-kinases–nuclear factor κB pathway in cardiomyocytes
|
|
Atrial amyloidosis identified by biopsy in atrial fibrillation: prevalence and clinical presentation
|
|
Mortality in male bodybuilding athletes
|
|
Cardiologist follow-up and improved outcomes of heart failure: a French nationwide cohort
|
|
Spatial transcriptional landscape of human heart failure
|
|
Lipoprotein(a) and recurrent atherosclerotic cardiovascular events: the US Family Heart Database
|
|
Low-density lipoprotein cholesterol, lipoprotein(a) and high-sensitivity C-reactive protein are independent predictors of cardiovascular events
|
|
|
Genes & Development
|
1 |
|
|
|
Genome Research
|
1 |
|
|
|
Gut
|
1 |
|
|
|
Hepatology
|
1 |
|
|
|
Human Reproduction
|
1 |
|
|
|
Immunity
|
4 |
|
|
|
Inorganic Chemistry
|
1 |
|
|
|
International Journal of Epidemiology
|
2 |
|
|
|
International Journal of Obesity
|
12 |
|
|
|
JAMA Internal Medicine
|
11 |
|
|
|
JAMA Pediatrics
|
5 |
|
|
|
JAMA Psychiatry
|
1 |
|
|
|
JAMA Surgery
|
2 |
|
|
|
JAMA: The Journal of the American Medical Association
|
29 |
|
|
|
Journal of Biological Chemistry
|
35 |
|
|
|
Journal of Bone and Joint Surgery-American Volume
|
1 |
|
|
|
Journal of Cleaner Production
|
1 |
|
|
|
Journal of Clinical Endocrinology & Metabolism
|
3 |
|
|
|
Journal of Clinical Investigation
|
31 |
|
|
|
Journal of Clinical Oncology
|
14 |
|
|
|
Journal of Experimental Medicine
|
3 |
|
|
|
Journal of Hepatology
|
1 |
|
|
|
Journal of Infectious Diseases
|
5 |
|
|
|
Journal of Physiology
|
56 |
|
|
|
Journal of Thoracic and Cardiovascular Surgery
|
108 |
|
|
|
Journal of the American Chemical Society
|
3 |
|
|
|
Journal of the American College of Cardiology
|
120 |
|
Aligning Coronary Stent Trial Enrollment With the U.S. Intended-Use Population
|
|
Sudden Cardiac Death Due to Myocardial Infarction With Obstructive and Nonobstructive Coronary Arteries
|
|
Randomized Trial of Left Bundle Branch Pacing vs Right Ventricular Pacing in Vulnerable Cardiac Function
|
|
Sudden Cardiac Death and its Relation to Previously Diagnosed or Occult Cardiac Disease at Autopsy
|
|
Focal and Diffuse Coronary Artery Disease Patterns and Placebo-Controlled Angina Relief With Percutaneous Coronary Intervention
|
|
Midlife Cardiorespiratory Fitness and Healthy Aging
|
|
Risk-Guided Atrial Fibrillation Screening With Artificial Intelligence–Enabled Electrocardiogram Models
|
|
Opportunistic Cardiovascular Risk Assessment Using Routine Head CT in the Emergency Department
|
|
Cardiovascular Disease Risk in Adults With Hematological Malignancies
|
|
Blood Pressure Trajectories and Cardiovascular Outcomes in Older Patients
|
|
Long-Term Cardiovascular and Noncardiovascular Mortality After Acute Coronary Syndrome
|
|
A Randomized, Placebo-Controlled Trial of Chronic Total Occlusion Percutaneous Coronary Intervention in Stable Angina - ORBITA-CTO
|
|
Automated Alerts to Improve Timely Evaluation and Treatment of Valvular Heart Disease: The ALERT Trial
|
|
Atrial Functional Mitral Regurgitation
|
|
Combining Genomics With Lipid and Inflammatory Biomarkers to Predict Coronary Artery Disease Risk
|
|
Cardiomyopathy Gene Variants and Polygenic Risk Scores in Atrial Fibrillation
|
|
Interchangeability of the KCCQ-12 and KCCQ-23 across gt;18,000 Participants Enrolled in 4 Large-Scale Trials of Heart Failure
|
|
Comparative Prognosis of Chagas and Other Cardiomyopathies
|
|
Use of Coronary Artery Calcium Scoring in Individuals With Elevated Lipoprotein(a)
|
|
Single-Ventricle Disease
|
|
Genotype-Guided Risk Stratification of Mitral Valve Surgery in Marfan Syndrome
|
|
Use of the Ross Procedure in North America
|
|
Real-Time Heart Team for Revascularization in Complex Coronary Artery Disease
|
|
Preferences for Antihypertensive Prescribing in Older Adults
|
|
Beta-Blocker (Bisoprolol) vs Calcium-Channel Blocker (Verapamil) in Nonobstructive Hypertrophic Cardiomyopathy
|
|
Sotatercept in Pulmonary Arterial Hypertension
|
|
Public Reporting and Case Selection in Congenital Heart Surgery Signals From a Multicenter Observational Study
|
|
Association Between Age and PCI Effectiveness in Stable CAD Secondary Analysis of ORBITA-2
|
|
Enhanced Detection and Prompt Diagnosis of Atrial Fibrillation Using Apple Watch A Randomized Controlled Trial
|
|
Blood Pressure Levels and Outcomes in Type 2 Diabetes Dose-Response Meta-Analysis of 5.87 Million Cohort Participants
|
|
Pulsed-Field Ablation to Enhance the Durability of Pulmonary Vein Isolation and Treat Paroxysmal Atrial Fibrillation
|
|
Hospitalizations and Mortality Among Medicare Beneficiaries at Cardiovascular Risk Disruptions and Recovery From the COVID-19 Pandemic
|
|
Natriuretic Peptide Receptor-1 Agonist for Resistant Hypertension A Randomized Phase 2 Trial
|
|
Echocardiographic Diastolic Function Grading in HFpEF Testing the Updated 2025 ASE Criteria
|
|
Heart Failure Quality of Care Among Asian Patients in the United States
|
|
Loss of Y Chromosome and Major Cardiovascular Events in a Prospective Study of Older Men
|
|
Delayed Diagnosis of Transthyretin Amyloid Cardiomyopathy in the Veterans Health Administration
|
|
Pulsed Field Ablation Using a Novel Biphasic Catheter vs Thermal Ablation for Paroxysmal Atrial Fibrillation InsightPFA Trial
|
|
Prevalence, Awareness, and Treatment of Hypertension in 37 African Countries Trends From 2003 to 2022
|
|
Association of Lp(a) With Cardiovascular Disease and All-Cause Mortality in U.S. Hispanics and Latinos
|
|
Early vs Late Staged PCI After Subintimal Tracking and Re-Entry for Chronic Total Occlusions A Randomized Trial
|
|
Trends in the Prevalence, Associated Risk Factors, and Health Burden of Heart Failure in the United States, 1988 to 2023
|
|
Trends in Prevalence, Treatment, and Control of Cardiometabolic Risk Factors Among Adults With Hypertension in the United States, 1999-2023
|
|
Aficamten in Obstructive Hypertrophic Cardiomyopathy: A Multi-Domain, Patient-Level Analysis of the MAPLE-HCM Trial
|
|
Potent P2Y12 Inhibitor Monotherapy versus DAPT after PCI in Patients With and Without STEMI: NEO-MINDSET Substudy
|
|
One-year outcomes of novel balloon-expandable versus contemporary transcatheter heart valves in severe aortic stenosis: the LANDMARK trial
|
|
Proactive Management and Treatment of Aortic Stenosis: An International Expert Perspective
|
|
Incremental Value of Cardiac Myosin-Binding Protein C for the Early Diagnosis of Acute Myocardial Infarction
|
|
Sex-Specific Microaxial Flow Pump Use and Outcomes in Infarct-Related Cardiogenic Shock in the DanGer Shock Trial
|
|
Follow-up Lipid Testing and Statin Initiation among Young Adults in a US Healthcare System
|
|
Multicenter Study on the Safety of Pulsed Field Ablation in Over 40,000 Patients: MANIFEST-US
|
|
Association of Lipoprotein(a) and Interleukin-6 With Cardiovascular Risk MESA and UK Biobank
|
|
Using Artificial Intelligence to Adjudicate Major Adverse Cardiovascular Events in Clinical Trials
|
|
Safety of Using Risk Stratification Along With High-Sensitivity Cardiac Troponin in the Emergency Department A Secondary Analysis
|
|
Using Transmitral Pressure Gradients and Residual Mitral Regurgitation to Optimize Outcome After Transcatheter Edge-to-Edge Repair
|
|
Tricuspid Regurgitation Across the Spectrum of Heart Failure With Preserved Ejection Fraction
|
|
Atrial Fibrillation Screening According to Genetic Risk A Secondary Analysis of the Randomized LOOP Study
|
|
Drug-coated balloon angioplasty versus upfront stenting for de novo CAD: 3-year follow-up of REC-CAGEFREE I trial
|
|
Intracoronary Low-Dose Recombinant Tissue Plasminogen Activator in Primary PCI for ST-Segment Elevation Myocardial Infarction and Large Thrombus Burden: A Randomized Trial
|
|
Long-Term Effect of ICDs in Nonischemic Heart Failure With Reduced Ejection Fraction Extended Follow-Up Analysis of DANISH
|
|
Using PREVENT Equations to Compare Intensive vs Standard Systolic Blood Pressure Control for Primary Prevention in SPRINT
|
|
Modest Effects of Intensive Blood Pressure–Lowering on Quality of Life in Patients at High Cardiovascular Risk The ESPRIT Trial
|
|
Intensive Blood Pressure Control in Older Patients With Hypertension 6-Year Results of the STEP Trial
|
|
Effects of Intensive Blood Pressure Control in Patients With Frailty A Post Hoc Analysis From ESPRIT
|
|
LDL-C related cardiovascular burden in China 2010-2030: Spatiotemporal patterns and scenario-based projections
|
|
Effect of Dapagliflozin on Quality of Life of Patients With Aortic Stenosis Undergoing Transcatheter Aortic Valve Implantation
|
|
Very High Prevalence of Nonoptimally Controlled Traditional Risk Factors at the Onset of Cardiovascular Disease
|
|
Mechanical Vacuum Aspiration and Debulking of Large Vegetations During Cardiac Implantable Electronic Device Extraction
|
|
Danicamtiv, a selective agonist of cardiac myosin, for dilated cardiomyopathy: A Phase 2 open-label trial
|
|
Association Between Anticoagulant Therapy and Survival in Pulmonary Arterial Hypertension A Registry Report and Updated Meta-Analysis
|
|
Remnant Cholesterol as an Independent Cardiovascular Risk Factor in Young Adults : An Age-Stratified Cohort Study
|
|
Intensive vs Conventional Intraoperative Blood Pressure Management on Cardiovascular Events After Major Abdominal Surgery The BP-CARES Randomized Trial
|
|
Safety and Effectiveness of Statins for Primary Prevention in Adults With Type 1 Diabetes An Emulation
|
|
Trajectories of Angina After Initial Invasive vs Conservative Strategy for Chronic Coronary Disease
|
|
Left Ventricular Health and TAVR Timing in Asymptomatic Severe Aortic Stenosis: Analysis from the EARLY TAVR Trial
|
|
Artificial Intelligence Automation of Echocardiographic Measurements
|
|
Pathogenic Cardiomyopathy-Associated Gene Variants and Prognosis in Atrial Fibrillation Results in 18,000 Clinical Trial Participants
|
|
Impact of Obicetrapib on Major Adverse Cardiovascular Events in High-Risk Patients A Pooled Analysis
|
|
Incidence of Heart Failure in Asian American, Native Hawaiian, and Other Pacific Islander Populations
|
|
Computed Tomography Angiography or Standard Care After Left Main PCI?
|
|
Sex Differences in Effectiveness of Semaglutide in Patients with Peripheral Artery Disease: The STRIDE Trial
|
|
Twice-A-Day CLOpidogrel vs Ticagrelor to Reduce Short-Term MACE after Primary PCI: The TADCLOT Trial
|
|
Personalized or Standard Duration of Dual Antiplatelet Therapy after Percutaneous Coronary Intervention: PARTHENOPE Randomized Trial
|
|
Colchicine and Longitudinal Dynamics of Clonal Hematopoiesis: An Exploratory Substudy of the LoDoCo2 Trial
|
|
A Polygenic Risk Score to Predict Incident Heart Failure Across the Spectrum of Cardiovascular Risk
|
|
Effect of Vericiguat on Worsening Heart Failure in Compensated Outpatients with HFrEF: Insights from VICTOR
|
|
Echocardiographic Changes With Mavacamten in Nonobstructive Hypertrophic Cardiomyopathy Exploratory Insights From the ODYSSEY-HCM Trial
|
|
Effect of Intensive Blood Pressure Control on Stroke A Prespecified Secondary Analysis of the ESPRIT Trial
|
|
Natriuretic Peptides, Body Mass Index, and Clinical Outcomes in Heart Failure with Mildly Reduced or Preserved Ejection Fraction
|
|
Causes of Myocardial Infarction in Younger Patients Troponin-Elevation in Persons ≤65 Years Old in Olmsted County
|
|
Effect of Aficamten Compared with Metoprolol on Echocardiographic Measures in Symptomatic Obstructive Hypertrophic Cardiomyopathy: MAPLE-HCM
|
|
Anthropometric Measures, Cardiovascular Outcomes, and Treatment Effects of Finerenone in Cardiovascular-Kidney-Metabolic Disease: Pooled Participant-Level Analysis of Three Global Trials
|
|
Effects of Mavacamten on Cardiac Biomarkers in Nonobstructive Hypertrophic Cardiomyopathy Insights From the ODYSSEY-HCM Trial
|
|
Prevalence and Predictors of Neurocognitive Dysfunction in Adults With Congenital Heart Disease Results From MINDS-ACHD
|
|
Clinical Outcomes of Conduction System Pacing vs Right Ventricular Septal Pacing in Atrioventricular Block The CSPACE Randomized Controlled Trial
|
|
Paclitaxel-Coated Balloon for the Treatment of Multilayer In-Stent Restenosis AGENT IDE Subgroup Analysis
|
|
Guideline-Directed Medical Therapy and Outcomes Among Patients With Heart Failure With Improved Ejection Fraction
|
|
Sodium-Glucose Cotransporter 2 Inhibitor With and Without an Aldosterone Antagonist for Heart Failure With Preserved Ejection Fraction The SOGALDI-PEF Trial
|
|
AHA PREVENT Equations and Cardiovascular Disease Risk in Diverse Health Care Populations
|
|
Global Impact of Fixed-Dose Combination Therapies on Cardiovascular Mortality and Events, 2023-2050 A Modeling Study
|
|
Plaque Vulnerability and Cardiovascular Risk Factor Burden in Acute Coronary Syndrome An Optical Coherence Tomography Analysis
|
|
Catheter Ablation vs Lifestyle Modification With Antiarrhythmic Drugs to Treat Atrial Fibrillation PRAGUE-25 Trial
|
|
3-Year Clinical Outcomes Comparing the Amulet vs Watchman FLX for Left Atrial Appendage Closure in Patients With Atrial Fibrillation Results From the SWISS-APERO Randomized Clinical Trial
|
|
One-Year Results from a Multi-Center Trial of a Polymer Surgical Mitral Valve: Insights into New Technology
|
|
Relationship Between Exercise-Induced Cardiac Troponin Elevations and Occult Coronary Atherosclerosis in Middle-Aged Athletes
|
|
Characterization of Arterial Aneurysms in Loeys-Dietz Syndrome
|
|
Differences in Arterial Events in Vascular Ehlers-Danlos, Loeys-Dietz, and Marfan Syndrome
|
|
Long-Term Survival and Patient-Reported Outcomes After Staged Reconstructive Surgery for Hypoplastic Left Heart Syndrome
|
|
Predicting Heart Failure Outcomes Using Patient-Reported Health Status Real-World Validation of the KCCQ-12
|
|
Long-Acting Factor XI Inhibition and Periprocedural Bleeding An Analysis From AZALEA-TIMI 71
|
|
Balloon Pulmonary Angioplasty for Chronic Thromboembolic Pulmonary Hypertension Results of an International Multicenter Prospective Registry
|
|
Lipoprotein(a), Cholesterol, Triglyceride Levels, and Vulnerable Coronary Plaques A PROSPECT II Substudy
|
|
Global Variation in Lipoprotein(a) Levels Among Patients With Coronary Heart Disease Insights From the INTERASPIRE Study and Implications for Emerging Lp(a)-Lowering Therapies
|
|
Recurrent Events Analysis of MASTER DAPT: Total Ischemic and Bleeding Events After Abbreviated vs Prolonged DAPT in HBR Patient
|
|
Valve Under-Expansion and Clinical Outcomes with ACURATE neo2: Findings from the ACURATE IDE Trial
|
|
Biolimus-Eluting Biomatrix Stent Versus a Dual-Therapy Sirolimus-Eluting Stent in PCI: SORT OUT XI Randomized Trial
|
|
10-Year Outcome of Complete or Infarct–Artery-Only Revascularization in STEMI with Multivessel Disease (DANAMI-3-PRIMULTI)
|
|
Ischemia on Dobutamine Stress Echocardiography Predicts Efficacy of PCI Results From the ORBITA-2 Trial
|
|
Disentangling the Impact of Adiposity From Insulin Resistance in Heart Failure With Preserved Ejection Fraction
|
|
Safety and Lipid-Lowering Efficacy of Inclisiran Monotherapy in Patients without ASCVD: The VICTORION-Mono Randomized Clinical Trial
|
|
|
Journal of the American Geriatrics Society
|
10 |
|
|
|
Journal of the American Society of Nephrology
|
7 |
|
|
|
Journal of the National Cancer Institute
|
8 |
|
|
|
Kidney International
|
2 |
|
|
|
Molecular Psychiatry
|
1 |
|
|
|
Nano Letters
|
3 |
|
|
|
Nature
|
9 |
|
|
|
Nature Communications
|
143 |
|
|
|
Nature Genetics
|
2 |
|
|
|
Nature Immunology
|
2 |
|
|
|
Nature Medicine
|
30 |
|
|
|
Nature Structural & Molecular Biology
|
1 |
|
|
|
Nature Sustainability
|
1 |
|
|
|
PLOS Genetics
|
6 |
|
|
|
PLOS Medicine
|
9 |
|
|
|
Proceedings of the National Academy of Sciences of the United States of America
|
35 |
|
|
|
Radiology
|
19 |
|
|
|
Science
|
5 |
|
|
|
Science Advances
|
23 |
|
|
|
Science Translational Medicine
|
12 |
|
|
|
Sustainable Cities and Society
|
2 |
|
|
|
The BMJ
|
7 |
|
|
|
The EMBO Journal
|
4 |
|
|
|
The ISME Journal: Multidisciplinary Journal of Microbial Ecology
|
2 |
|
|
|
The Journal of Allergy and Clinical Immunology
|
25 |
|
|
|
The Lancet
|
28 |
|
Prediction of mortality, bleeding, and ischaemic events in patients with cancer and acute coronary syndrome: a model development and validation study
|
|
Abluminus DES+ sirolimus-eluting stent versus everolimus-eluting stent in patients with diabetes and coronary artery disease (ABILITY Diabetes Global): results from a multicentre, randomised controlled trial
|
|
Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial
|
|
Tafasitamab, lenalidomide, and rituximab in relapsed or refractory follicular lymphoma (inMIND): a global, phase 3, randomised controlled trial
|
|
Transcatheter aortic valve implantation with the Trilogy valve for symptomatic native aortic regurgitation (ALIGN-AR): a pivotal, multicentre, single-arm, investigational device exemption study
|
|
Complete versus culprit lesion-only revascularisation for acute myocardial infarction (Complete Revascularisation Trialists' Collaboration): an individual patient data meta-analysis of randomised trials
|
|
Percutaneous transcatheter valve replacement in individuals with mitral regurgitation unsuitable for surgery or transcatheter edge-to-edge repair: a prospective, multicountry, single-arm trial
|
|
Dual antiplatelet therapy after percutaneous coronary intervention according to bleeding risk (HOST-BR): an open-label, multicentre, randomised clinical trial
|
|
Sultiame once per day in obstructive sleep apnoea (FLOW): a multicentre, randomised, double-blind, placebo-controlled, dose-finding, phase 2 trial
|
|
Ibrutinib and rituximab versus immunochemotherapy in patients with previously untreated mantle cell lymphoma (ENRICH): a randomised, open-label, phase 2/3 superiority trial
|
|
Budesonide–formoterol versus salbutamol as reliever therapy in children with mild asthma (CARE): a 52-week, open-label, multicentre, superiority, randomised controlled trial
|
|
Effect of evolocumab on saphenous vein graft patency after coronary artery bypass surgery (NEWTON-CABG CardioLink-5): an international, randomised, double-blind, placebo-controlled trial
|
|
Immediate versus staged complete revascularisation during index admission in patients with ST-segment elevation myocardial infarction and multivessel disease (OPTION–STEMI): a multicentre, non-inferiority, open-label, randomised trial
|
|
Paclitaxel-coated versus uncoated devices for infrainguinal endovascular revascularisation in patients with intermittent claudication (SWEDEPAD 2): a multicentre, participant-masked, registry-based, randomised controlled trial
|
|
Benefit–harm trade-offs of intensive blood pressure control versus standard blood pressure control on cardiovascular and renal outcomes: an individual participant data analysis of randomised controlled trials
|
|
Paclitaxel-coated versus uncoated devices for infrainguinal endovascular revascularisation in chronic limb-threatening ischaemia (SWEDEPAD 1): a multicentre, participant-masked, registry-based, randomised controlled trial
|
|
Clopidogrel versus aspirin for secondary prevention of coronary artery disease: a systematic review and individual patient data meta-analysis
|
|
Vericiguat for patients with heart failure and reduced ejection fraction across the risk spectrum: an individual participant data analysis of the VICTORIA and VICTOR trials
|
|
Vericiguat in patients with chronic heart failure and reduced ejection fraction (VICTOR): a double-blind, placebo-controlled, randomised, phase 3 trial
|
|
β blockers after myocardial infarction with mildly reduced ejection fraction: an individual patient data meta-analysis of randomised controlled trials
|
|
Blood pressure-lowering efficacy of antihypertensive drugs and their combinations: a systematic review and meta-analysis of randomised, double-blind, placebo-controlled trials
|
|
Spironolactone versus placebo in patients undergoing maintenance dialysis (ACHIEVE): an international, parallel-group, randomised controlled trial
|
|
Spironolactone in patients on chronic haemodialysis at high risk of adverse cardiovascular outcomes (ALCHEMIST): a multicentre, double-blind, randomised, placebo-controlled trial and updated meta-analysis
|
|
Collaboration on the optimal timing of anticoagulation after ischaemic stroke and atrial fibrillation: a systematic review and prospective individual participant data meta-analysis of randomised controlled trials (CATALYST)
|
|
Mitapivat in adults with non-transfusion-dependent α-thalassaemia or β-thalassaemia (ENERGIZE): a phase 3, international, randomised, double-blind, placebo-controlled trial
|
|
ACURATE neo2 valve versus commercially available transcatheter heart valves in patients with severe aortic stenosis (ACURATE IDE): a multicentre, randomised, controlled, non-inferiority trial
|
|
Safety and efficacy of a novel ANGPTL4 inhibitory antibody for lipid lowering: results from phase 1 and phase 1b/2a clinical studies
|
|
Fixed-dose combination of obicetrapib and ezetimibe for LDL cholesterol reduction (TANDEM): a phase 3, randomised, double-blind, placebo-controlled trial
|
|
|
The Lancet Diabetes & Endocrinology
|
3 |
|
|
|
The Lancet Global Health
|
4 |
|
|
|
The Lancet Neurology
|
2 |
|
|
|
The Lancet Oncology
|
1 |
|
|
|
The New England Journal of Medicine
|
55 |
|
|
|
Thorax
|
52 |
|
Association of blood eosinophils and exhaled nitric oxide with exacerbations in patients with asthma, COPD and asthma+COPD: the NOVELTY study
|
|
Association between overuse of short-acting β2-agonists and the risk of major adverse cardiovascular events among patients with asthma
|
|
At-risk registers integrated into primary care to stop asthma crises in the UK: cluster randomised controlled trial with economic evaluation
|
|
Altitude-induced periodic breathing optimises respiratory efficiency during sleep in young healthy males
|
|
Correlates of 5-year decline in 6-min walk distance in the COPDGene cohort
|
|
Clinical and cost-effectiveness of SPACE for COPD delivered as a pulmonary rehabilitation maintenance programme: a randomised controlled trial
|
|
Atomoxetine plus oxybutynin for obstructive sleep apnoea: a randomised-controlled trial with detailed pathophysiology
|
|
Comparison of Lower Airway Sampling Strategies in Children with Protracted Bacterial Bronchitis (CLASSIC-PBB): a non-randomised, internally controlled, multicentre trial
|
|
Short-term effects of size-fractioned particulate matter on blood pressure in patients with COPD: the key role of inflammatory phenotypes
|
|
Development and validation of the Hypersensitivity Pneumonitis South Asian Questionnaire for Exposure (HP-SAQE): a novel, qualitative and quantitative tool
|
|
Acetazolamide to prevent ventilatory drive withdrawal in REM sleep apnoea: a randomised controlled trial
|
|
Loop gain predicts residual sleep apnoea among people using positive airway pressure
|
|
Transcriptomic signatures of IPF in ALI-cultured airway cells and their therapeutic implications
|
|
Clinical, molecular and microbial characterisation of the eosinophilic endotype of bronchiectasis: data from the EMBARC-BRIDGE study
|
|
Impact of air pollution on lung function in cystic fibrosis over a decade in London: a UK CF Registry study
|
|
Extreme value analysis has the potential to improve spirometry interpretation
|
|
Incidence and prevalence of obstructive sleep apnoea and narcolepsy in the UK: a population-based descriptive study
|
|
Clinical impact of customised positive airway pressure (PAP) therapy interfaces (3DPiPPIn): a single site randomised controlled trial
|
|
Antifibrotic therapy and lung cancer risk in patients with idiopathic pulmonary fibrosis: a large retrospective propensity-weighted cohort study
|
|
Elastic parametric response mapping: quantitative CT scoring for local COPD severity
|
|
Development and validation of PRECISE-X model: predicting first severe exacerbation in COPD
|
|
Disproportionate increase in COPD exacerbation risk for 3 months after discontinuing LAMA or ICS: insights from the FLAME trial
|
|
Heterogeneity of short-term elexacaftor-tezacaftor-ivacaftor response in cystic fibrosis using 129Xe MRI
|
|
Blood eosinophil-guided systemic corticosteroid duration in adults hospitalised for asthma exacerbation: a randomised, controlled, open-label, non-inferiority trial
|
|
Disproportionate impairment in diffusing capacity predicts pulmonary hypertension with an elevated pulmonary vascular resistance in COPD
|
|
Multidisciplinary, non-pharmacological breathlessness intervention service for patients with moderately severe to severe COPD: a randomised controlled trial
|
|
Understanding the bidirectional relationship between chronic respiratory disease and cardiovascular disease using genetic evidence
|
|
Sex differences in outcome after endoscopic lung volume reduction (ELVR) in patients with emphysema: a retrospective analysis of the German Lung Emphysema Registry (LER e.V.)
|
|
Time to diagnosis and long-term outcomes for adults presenting with breathlessness
|
|
Safety, feasibility and efficacy of exercise as an airway clearance technique in cystic fibrosis: a randomised pilot feasibility trial
|
|
Proteomics-based risk prediction and drug targets identification for chronic obstructive pulmonary disease
|
|
Mobile health pulmonary rehabilitation (m-PR): a randomised controlled equivalence trial
|
|
Acute breathlessness as a cause of hospitalisation in Malawi: a prospective, patient-centred study to evaluate causes and outcomes
|
|
Adherence to the EAT-Lancet diet, plasma proteomics and the risk of chronic obstructive pulmonary disease
|
|
Serum IgA isotypes are associated with percent emphysema, wall thickness and lung function decline
|
|
Factors associated with guideline-concordant maintenance inhaled medication for COPD: a population-based, longitudinal cohort study
|
|
Efficacy and safety of novel airway balloon cryoablation system for malignant central airway obstruction: a prospective, multicentre, randomised, non-inferiority study
|
|
Effect of simvastatin on postoperative complications in patients undergoing one-lung ventilation during surgery: the Prevention HARP-2 randomised controlled trial
|
|
Home and outpatient versus in-hospital initiation of non-invasive ventilation in people with neuromuscular and restrictive thoracic disorders: a network meta-analysis
|
|
PM2.5 as a risk factor for sleep oxygen desaturation in COPD: identifying susceptible individuals by smoking and inflammatory phenotypes
|
|
Basement membrane repair response biomarker PRO-C4 predicts progression in idiopathic pulmonary fibrosis: analysis of the PFBIO and PROFILE cohorts
|
|
Inhalational exposures associated with risk of interstitial lung disease: a systematic review and meta-analysis
|
|
Associations of interstitial lung disease subtype and CT pattern with lung function and survival
|
|
Optimised oxygenation improves functional capacity during daily activities in patients with COPD on long-term oxygen therapy: a randomised crossover trial
|
|
Circulating miRNAs and childhood asthma ICS response: a stratified analysis in the intervention arm of an RCT with vitamin D effect modification
|
|
Randomised, placebo-controlled trial of oral hymecromone in adults with pulmonary hypertension
|
|
1-year physical activity coaching programme in lung transplant recipients: an RCT
|
|
Effect of elexacaftor/tezacaftor/ivacaftor on systemic inflammation in cystic fibrosis
|
|
129Xe-MRI ventilation and acinar abnormalities highlight the significance of spirometric dysanapsis: findings from the NOVELTY ADPro UK substudy
|
|
Systematic review and meta-analysis of the efficacy of biologic and targeted synthetic therapies in sarcoidosis
|
|
Impact of long-term non-invasive ventilation on severe exacerbations and survival in COPD: a French nationwide cohort study using multistate models
|
|
High rates of post-tuberculosis lung disease among persons successfully treated for drug-susceptible and resistant tuberculosis
|
|